Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS [myelodysplastic syndrome] or AML [acute myeloid leukaemia] Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study,

Next Previous
X
Search
Trial Profile

Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS [myelodysplastic syndrome] or AML [acute myeloid leukaemia] Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study,

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan; Cyclophosphamide; Cytarabine; Gemtuzumab ozogamicin; Idarubicin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 16 Jul 2012 Biomarkers information updated
    • 13 Jul 2012 Actual end date (1 Nov 2006) added as reported by ClinicalTrials.gov.
    • 06 Jul 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top